← Back to Screener
Jazz Pharmaceuticals, Inc. (JAZZ)
Price$232.64
Value ScoreC
Growth ScoreC
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)18.64%
Price vs S&P 500 (4W)11.69%
VGM Score54.92
Market Capitalization$14.84B
P/E Ratio (Annual)19.93x
All Metrics
P/CF (Annual)10.94x
Book Value / Share (Quarterly)$72.29
P/TBV (Annual)6.28x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)5.26%
Cash Flow / Share (Quarterly)$18.24
Price vs S&P 500 (YTD)28.18%
Gross Margin (TTM)88.00%
Net Profit Margin (TTM)0.66%
EPS (TTM)$0.11
10-Day Avg Trading Volume0.90M
EPS Excl Extra (TTM)$0.11
Revenue Growth (5Y)12.54%
EPS (Annual)$-5.84
ROI (Annual)-3.68%
Gross Margin (Annual)88.21%
Net Profit Margin (5Y Avg)-0.11%
Cash / Share (Quarterly)$45.84
P/E Basic Excl Extra (TTM)503.10x
Revenue Growth QoQ (YoY)19.05%
EPS Growth (5Y)-1.36%
P/E Normalized (Annual)19.93x
ROA (Last FY)-3.05%
Revenue Growth TTM (YoY)9.20%
EBITD / Share (TTM)$10.16
ROE (5Y Avg)0.19%
Operating Margin (TTM)-0.85%
Cash Flow / Share (Annual)$18.65
P/B Ratio3.27x
P/B Ratio (Quarterly)2.57x
Net Income / Employee (Annual)$-123,200
EV / Revenue (TTM)4.13x
Net Interest Coverage (TTM)-2.18x
ROA (TTM)0.26%
EPS Growth QoQ (YoY)7.21%
EV / EBITDA (TTM)28.91x
EPS Incl Extra (Annual)$-5.84
Current Ratio (Annual)1.86x
Quick Ratio (Quarterly)1.78x
3-Month Avg Trading Volume0.94M
52-Week Price Return118.45%
EV / Free Cash Flow (Annual)16.01x
P/E Incl Extra (TTM)503.10x
Revenue / Employee (TTM)$1,535,900
Tangible BV / Share (Quarterly)$5.24
P/S Ratio (Annual)3.48x
Asset Turnover (Annual)0.37x
52-Week High$243.32
Operating Margin (5Y Avg)5.27%
EPS Excl Extra (Annual)$-5.84
CapEx CAGR (5Y)-11.17%
Tangible BV CAGR (5Y)42.31%
26-Week Price Return34.57%
Quick Ratio (Annual)1.60x
13-Week Price Return25.15%
Total Debt / Equity (Annual)1.24x
Current Ratio (Quarterly)2.04x
Enterprise Value$18.35B
Revenue / Share Growth (5Y)10.84%
Asset Turnover (TTM)0.39x
Book Value / Share Growth (5Y)1.47%
Revenue / Employee (Annual)$1,476,700
Inventory Turnover (Annual)1.12x
Pretax Margin (Annual)-14.71%
Cash / Share (Annual)$39.75
3-Month Return Std Dev29.84%
Gross Margin (5Y Avg)87.38%
Net Income / Employee (TTM)$10,200
EBITDA CAGR (5Y)-18.72%
EBITDA Interim CAGR (5Y)17.18%
ROE (Last FY)-8.25%
Net Interest Coverage (Annual)-0.21x
EPS Basic Excl Extra (Annual)$-5.84
P/FCF (TTM)12.97x
Receivables Turnover (TTM)5.96x
EV / Free Cash Flow (TTM)16.04x
Total Debt / Equity (Quarterly)1.18x
EPS Incl Extra (TTM)$0.11
Receivables Turnover (Annual)5.52x
ROI (TTM)0.31%
P/S Ratio (TTM)3.34x
Pretax Margin (5Y Avg)-1.84%
Revenue / Share (Annual)$69.98
Tangible BV / Share (Annual)$26.16
Forward P/E9.29x
Free OCF CAGR (5Y)17.11%
Price vs S&P 500 (52W)90.24%
P/E Ratio (TTM)503.10x
EPS Growth TTM (YoY)-98.57%
Year-to-Date Return39.11%
5-Day Price Return-1.39%
EPS Normalized (Annual)$-5.84
ROA (5Y Avg)0.10%
Net Profit Margin (Annual)-8.35%
Month-to-Date Return16.49%
Cash Flow / Share (TTM)$10.05
EBITD / Share (Annual)$3.68
Operating Margin (Annual)-10.08%
LT Debt / Equity (Annual)1.00x
P/CF (TTM)11.12x
ROI (5Y Avg)0.07%
P/E Excl Extra (TTM)503.10x
LT Debt / Equity (Quarterly)0.95x
EPS Basic Excl Extra (TTM)$0.11
P/TBV (Quarterly)35.43x
P/B Ratio (Annual)2.39x
Inventory Turnover (TTM)1.15x
Pretax Margin (TTM)-4.93%
Book Value / Share (Annual)$70.30
Price vs S&P 500 (13W)15.40%
Net Margin Growth (5Y)-10.67%
Beta0.33x
P/FCF (Annual)12.95x
Revenue / Share (TTM)$67.15
ROE (TTM)0.71%
52-Week Low$105.00
vGradeC
gGradeC
mGradeB
vgmGradeC
Show chart for
Earnings Surprise History
Q1 266.34est. 4.66
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.26
4.26
4.26
4.25
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
JAZZJazz Pharmaceuticals, Inc. | C | C | B | $232.64 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical company with approved treatments in neuroscience and oncology. Its portfolio of nine drugs includes leading franchises such as Xyrem/Xywav for narcolepsy, Epidiolex for severe epilepsy (acquired in 2021 from GW Pharmaceuticals), and oncology medications including Zepzelca, Rylaze, and Vyxeos. The company focuses on high-unmet-need therapeutic areas with limited competitive options.